CbzAsnPheCH2Cl | 132234-37-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: CbzAsnPheCH2Cl
• 英文别名: Cbz-Asn-Phe-CH2Cl；benzyl N-[(2S)-4-amino-1-[[(2S)-4-chloro-3-oxo-1-phenylbutan-2-yl]amino]-1,4-dioxobutan-2-yl]carbamate
• CAS: 132234-37-8
• 化学式: C₂₂H₂₄ClN₃O₅
• 分子量: 445.903
• InChiKey: VHLUMFWONFKFSM-ROUUACIJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  31
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  128
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  CbzAsnPheCH2Cl 在 sodium tetrahydroborate 、 碳酸氢钠 、 sodium iodide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 (S)-2-[(2S,3S)-2-({(S)-1-[(S)-3-((S)-2-Benzyloxycarbonylamino-3-carbamoyl-propionylamino)-2-hydroxy-4-phenyl-butyl]-pyrrolidine-2-carbonyl}-amino)-3-methyl-pentanoylamino]-3-methyl-butyric acid methyl ester
  参考文献：
  名称：

  New hydroxyethylamine HIV protease inhibitors that suppress viral replication

  摘要：

  The synthesis of analogues of AcSerLeuAsn[Phe-HEA-Pro]IleValOMe (1, JG-365; where HEA stands for the hydroxyethylamine unit 2), a tight-binding inhibitor of HIVP, are reported. Systematic modification of the P3 and P3' regions of the inhibitors has led to smaller HIVP inhibitors that inhibit viral replication in HIV-infected and SIV-infected cell cultures. Six aliphatic and/or aromatic derivatives were prepared by replacing residues in the P3 regions of BocLeuAsn[Phe-HEA-Pro]IleValOMe. Aromatic side chains at P3 gave better inhibitors than aliphatic side chains. The better inhibitors in this series contained a beta-naphthylalanine or a biphenyl unit at P3. A second series of HIVP inhibitors were obtained by converting the P3 group into acyl groups. CbzAsn[Phe-HEA-Pro]IlePheOMe and Qua-Asn-[Phe-HEA-Pro]-Ile-Phe-OMe (where Qua = quinolin-2-ylcarbonyl) are potent HIVP inhibitors with K(i) values equal to 1.0 and 0.1 nM, respectively. The inhibition constants were determined by using the continuous fluorometric assay developed by Toth and Marshall. The activities of the protease inhibitors for inhibition of SIV replication were determined in vitro using CEMX174 cells. Inhibition of HIV infection was determined essentially as reported by Pauwels and co-workers. The anti-HIV assay was carried out in culture using CEM cell (a CD4+ lymphocyte line) infected with virus strain HTLV-IIIb with a multiplicity of infection of 0.1. Several analogues inhibited the cytopathic effect at concentrations of 0.1-0.8 mug/mL. These results establish that good inhibitors of HIV protease that inhibit viral replication in infected lymphocytes in in vitro cell assays can be obtained from JG-365 when the AcSerLeu unit is replaced by aromatic acyl derivatives.

  DOI：

  10.1021/jm00099a008

文献信息

• [EN] PEPTIDE INHIBITORS OF HIV PROTEASE
  申请人：WISCONSIN ALUMNI RESEARCH FOUNDATION

  公开号：WO1991008221A1

  公开（公告）日：1991-06-13

  (EN) The invention provides HIV protease inhibitors which are potential drugs for HIV infected patients or cells. Preferably, peptides are provided that have an amino alcohol core that mimics a Phe-Pro and/or Leu-Pro binding site for the protease. The core is preferably ringed by at least three amino acids. In one form, an N-terminal cap is positioned adjacent to an Asn residue.(FR) L'invention concerne des inhibiteurs de protéase d'HIV qui constituent des médicaments potentiels pour des malades ou des cellules contaminés avec le virus HIV. De préférence, des peptides possèdent un noyau d'amino-alcool qui simule un site de liaison Phe-Pro et/ou Leu-Pro pour la protéase. Le noyau est de préférence entouré par au moins trois acides aminés. Selon une réalisation, l'extrémité d'une terminaison -N est positionnée adjacente à un reste d'Asn.
• New hydroxyethylamine HIV protease inhibitors that suppress viral replication
  作者：Daniel H. Rich、J. V. N. Vara Prasad、Chong Qing Sun、Jeremy Green、Richard Mueller、Kathryn Houseman、Debra MacKenzie、Miroslav Malkovsky

  DOI：10.1021/jm00099a008

  日期：1992.10

  The synthesis of analogues of AcSerLeuAsn[Phe-HEA-Pro]IleValOMe (1, JG-365; where HEA stands for the hydroxyethylamine unit 2), a tight-binding inhibitor of HIVP, are reported. Systematic modification of the P3 and P3' regions of the inhibitors has led to smaller HIVP inhibitors that inhibit viral replication in HIV-infected and SIV-infected cell cultures. Six aliphatic and/or aromatic derivatives were prepared by replacing residues in the P3 regions of BocLeuAsn[Phe-HEA-Pro]IleValOMe. Aromatic side chains at P3 gave better inhibitors than aliphatic side chains. The better inhibitors in this series contained a beta-naphthylalanine or a biphenyl unit at P3. A second series of HIVP inhibitors were obtained by converting the P3 group into acyl groups. CbzAsn[Phe-HEA-Pro]IlePheOMe and Qua-Asn-[Phe-HEA-Pro]-Ile-Phe-OMe (where Qua = quinolin-2-ylcarbonyl) are potent HIVP inhibitors with K(i) values equal to 1.0 and 0.1 nM, respectively. The inhibition constants were determined by using the continuous fluorometric assay developed by Toth and Marshall. The activities of the protease inhibitors for inhibition of SIV replication were determined in vitro using CEMX174 cells. Inhibition of HIV infection was determined essentially as reported by Pauwels and co-workers. The anti-HIV assay was carried out in culture using CEM cell (a CD4+ lymphocyte line) infected with virus strain HTLV-IIIb with a multiplicity of infection of 0.1. Several analogues inhibited the cytopathic effect at concentrations of 0.1-0.8 mug/mL. These results establish that good inhibitors of HIV protease that inhibit viral replication in infected lymphocytes in in vitro cell assays can be obtained from JG-365 when the AcSerLeu unit is replaced by aromatic acyl derivatives.